The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLMC 2020 | The future of CLL treatment: more selective and reversible BTK inhibitors
Jenifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the future directions of research into treatments for chronic lymphocytic leukemia (CLL). Dr Woyach highlights ongoing research on acalabrutinib which may offer safety benefits over existing standard of care regimens (NCT04008706) and treatment options for patients who have progressed following BTK inhibitor treatment using reversible BTK inhibitors, including Phase I/II trials of LOXO-305 (NCT03740529) and nemtabrutinib (ARQ 531) (NCT03162536). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consulting/advisory boards: Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule
